ReviewUS cardiology2025
Cardiogenic Shock in Restrictive Cardiomyopathies: What We Know So Far.
Review in US cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiogenic Shock: Clinical Management, Outcomes and Future Directions.Journal of cardiovascular development and disease · 2026Review
- Heart Failure Wired from Shock to Devices and Home: A New Era of Delivery.US cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiogenic shock (CS) is a severe and life-threatening condition caused by the heart's inability to provide adequate blood flow, leading to systemic hypoperfusion and multiorgan dysfunction. While acute MI and heart failure with reduced ejection fraction are common causes of CS, restrictive cardiomyopathy (RCM) presents a unique challenge due to its underlying hemodynamic complexities related to myocardial stiffness. RCM is characterized by preserved systolic function but impaired ventricular filling, resulting in elevated diastolic pressures and a tendency for rapid decompensation into shock. This review explores the pathophysiology, diagnostic evaluation, and management of CS in RCM. Diagnostic tools such as echocardiography and hemodynamic monitoring are critical for differentiating the causes of CS. Treatment strategies focus on optimizing volume status, arrhythmia control, and, in some cases, mechanical circulatory support. Heart transplantation remains the definitive treatment for eligible patients. Early recognition and tailored interventions are essential for the enhancement of survival and quality of life in these critically ill patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.